Par Pharmaceutical: High-Quality, Cost-Effective Generic Products
Par Pharmaceutical, headquartered in Chestnut Ridge, New York, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a robust research and development (R&D) pipeline of potential products. Par is an operating company of Endo International plc, a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
Location: United States, New York, Village of Chestnut Ridge
Employees: 1001-5000
Founded date: 1978
Investors 1
Mentions in press and media 7
| Date | Title | Description | Source |
| 12.03.2024 | Par Pharmaceutical Issues Voluntary Nationwide Recall of One... | COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA ... | einpresswi... |
| 17.07.2012 | Par Pharmaceuticals’ generic appeal attracts $1.9 billion pr... | There has been quite a bit of crossover between generic and branded pharmaceutical companies with th... | medcitynew... |
| 25.11.2011 | Pozen inks $75M U.S. royalty deal for Treximet with Canadian... | For the first nine months of 2011, revenues from royalties on Treximet were of $12.2 million, accord... | medcitynew... |
| 22.03.2011 | N.C. pharma Pozen files court challenge to block generic com... | Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Healt... | medcitynew... |
| - | N.C. pharma Pozen files court challenge to block generic com... | Looming patent expiration on the migraine drug Treximet has led pharmaceutical company Pozen to take... | medcitynew... |
| - | Par Pharmaceuticals’ generic appeal attracts $1.9 billion pr... | Generics producer Par Pharmaceuticals (NYSE: PRX) has been snapped up by a global private equity fir... | medcitynew... |
| - | Pozen inks $75M U.S. royalty deal for Treximet with Canadian... | Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national... | medcitynew... |